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Sir,
We thank Heong et al (2010) for their interest in our study on
chemotherapy treatment pathways of advanced colorectal cancer
(CRC) patients in the United Kingdom (Shabaruddin et al, 2010a).
The purpose of our national survey of UK consultant oncologists
was to identify predominant treatment pathways within NHS
CRC specialties and to determine the extent of variation within
current practice. Economic models need to establish current
practice as a basis from which to evaluate the incremental cost and
benefits of introducing a new intervention, such as the UGT1A1
pharmacogenetic test.
In the United Kingdom, available national data sets do not
provide the level of detail needed to describe current clinical
practice and the respective outcomes. Some cancer-related
registries do exist, such as the UK Association of Cancer Registries
and the National Bowel Cancer Audit Programme for CRC
surgeries, but do not contain data relevant to current clinical
practice in oncology specialties. The National Cancer Intelligence
Network (http://www.ncin.org.uk) is currently conducting a
chemotherapy data set review that aims to capture data on all
chemotherapy carried out in the country. The level of detail for the
data collected is yet to be determined. It is necessary to consider
that comprehensive UK NHS patient registries are not an easy
option. The size of the NHS, funding constraints, issues with data
management and quality assurance challenges preclude the
establishment and maintenance of such registries for all conditions
across the United Kingdom. In an ideal world, information
technology in the NHS should allow extraction of data on current
practice. This ideal situation does not exist in the current NHS
(Anderson, 2010).
In the absence of real-world data on routine care, other means
of generating parameters to inform economic analyses are
necessary, which may be sufficient depending on the purpose of
the evaluation (Cooper et al, 2007). Expert estimates are useful
starting points to describe current practice and patients’ clinical
pathways. It is necessary to elicit expert estimates from across the
United Kingdom rather than from one locality in order to
understand the variation in routine NHS practice.
Economic models allow the systematic compilation of data from
various sources, such as epidemiological studies and clinical trials,
within a single framework. Expert estimates are primarily used to
inform model parameters in the absence of other data sources. The
degrees of uncertainty in the parameters are then explored using
the ranges and measures of variation from the expert estimates.
An economic model will allow for exploration of the key areas of
uncertainties, generate the expected value of further research to
minimise these uncertainties and help inform what research
should be conducted to address them. Value of information
analysis can indicate whether funding is better directed to more
clinical trials or to setting up robust observational studies.
We believe that the usefulness of expert estimates will only be as
good as the design, construct and framing of the questions asked.
Our final questionnaire was informed by a pilot study of eight
consultant oncologists. To address the concern of Heong et al
regarding the agreement between expert estimates and standard
practice, we present (Table 1) preliminary results from an
observational study of 48 advanced CRC patients on IrMdG
chemotherapy in a UK NHS tertiary care oncology centre
(Shabaruddin et al, 2010b), in which there were similar parameters
with the experts’ estimates (Shabaruddin et al, 2010a).
Currently, on the basis of our data, there is no evidence to suggest
that pooled UK experts’ estimates varied widely from routine NHS
practice. In the absence of other data sources, we believe that expert
opinion is useful to inform economic evaluations and to help focus
research resources by identifying key areas of uncertainties that
offer the best value for future research investments.
Finally, we do agree with Heong et al on the need to collect data
on current clinical practice and acknowledge the value of access to
such data. The key question from the UK perspective is: who will
pay and be responsible for collecting, storing and maintaining data
on routine NHS clinical practice?
Table 1 Expert estimates from 44 NHS consultant oncologists
compared with data from an observational study at a UK tertiary care
oncology centre
Parameter
Expert
estimates Observational study
Duration of IrMdG
chemotherapy
Mean duration
5.0 months
Mean duration 5.0 months (first line 5.2
months, second line 4.7 months)
Incidence of febrile
neutropenia (%)
8.4 8.3
Abbreviation: IrMdG¼irinotecan (180 mgm
 2) with infusional 5-FU according to
MdG regimen. Published online 9 November 2010
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